{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:29:41Z","timestamp":1792726181085,"version":"4.5.0"},"reference-count":99,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec id=\"ab-orv260002-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Despite gains in understanding head and neck cancer over the past several decades, the discovery of reliable biomarkers remains elusive. With the advent of human papillomavirus\u2013associated oropharynx cancer and Epstein-Barr virus\u2013associated nasopharynx cancer, circulating tumor DNA (ctDNA) and oncogenic viral DNA have emerged as potentially promising biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-orv260002-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>A review was conducted by the American Head and Neck Society to address the current utility of ctDNA. Ongoing clinical trials were reviewed, with discussion of its utility in monitoring treatment response and measuring minimal residual disease (MRD). Although ctDNA holds promise in the push for precision oncology, several questions remain regarding its routine clinical use, including test variability and implications of inaccurate test results. Optimized clinical trial designs and further research are necessary to bring ctDNA to the forefront of head and neck cancer management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-orv260002-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Liquid biopsy targeting viral ctDNA is a promising biomarker in the diagnostic and surveillance settings across head and neck cancer types. Ongoing clinical trials will help elucidate how ctDNA can be implemented to monitor treatment response, assess MRD, and frame treatment decisions to adapt treatment via a precision oncology approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoto.2026.2045","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:30:31Z","timestamp":1785425431000},"page":"905","source":"Crossref","is-referenced-by-count":2,"title":["Circulating Tumor DNA in Head and Neck Cancer"],"prefix":"10.1001","volume":"152","author":[{"given":"Sagar","family":"Kansara","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Louisiana State University Health Sciences Center, New Orleans"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Contrera","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Roof","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Mount Sinai School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Kane","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Alabama, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rula","family":"Mualla","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Louisiana State University Health Sciences Center, New Orleans"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Rettig","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Section of Otolaryngology\u2013Head and Neck Surgery, University of Chicago School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Wenig","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Illinois, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Thomas Jefferson University School of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Faden","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts"},{"name":"Massachusetts Eye and Ear, Mass General Hospital, Broad Institute, Cambridge"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Holsinger","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"orv260002r1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"orv260002r2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.oraloncology.2013.12.019","article-title":"Epidemiology of HPV-associated oropharyngeal cancer.","volume":"50","author":"Pytynia","year":"2014","journal-title":"Oral Oncol"},{"issue":"1","key":"orv260002r3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer.","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"orv260002r4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.radonc.2017.10.018","article-title":"Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: the MARCH-HPV project.","volume":"126","author":"Lassen","year":"2018","journal-title":"Radiother Oncol"},{"issue":"8","key":"orv260002r5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"orv260002r6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12943-022-01551-7","article-title":"A clinician\u2019s handbook for using ctDNA throughout the patient journey.","volume":"21","author":"Hasenleithner","year":"2022","journal-title":"Mol Cancer"},{"issue":"2","key":"orv260002r7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/v13020321","article-title":"Persistent human papillomavirus infection.","volume":"13","author":"Della Fera","year":"2021","journal-title":"Viruses"},{"key":"orv260002r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2025.107262","article-title":"Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: a systematic review.","volume":"164","author":"Chennareddy","year":"2025","journal-title":"Oral Oncol"},{"issue":"11","key":"orv260002r9","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/hed.27515","article-title":"It is time to improve the diagnostic workup of oropharyngeal cancer with circulating tumor HPV DNA: systematic review and meta-analysis.","volume":"45","author":"Paolini","year":"2023","journal-title":"Head Neck"},{"issue":"3","key":"orv260002r10","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/ohn.1056","article-title":"Methodology of cfHPV-DNA detection in head and neck cancer: a systematic review and meta-analysis.","volume":"172","author":"Thomas","year":"2025","journal-title":"Otolaryngol Head Neck Surg"},{"key":"orv260002r11","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00276","article-title":"Detection of early human papillomavirus-associated cancers by liquid biopsy.","author":"Damerla","journal-title":"JCO Precis Oncol"},{"issue":"15","key":"orv260002r12","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer.","volume":"25","author":"Chera","year":"2019","journal-title":"Clin Cancer Res"},{"key":"orv260002r13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.oraloncology.2019.06.019","article-title":"Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer.","volume":"95","author":"Hanna","year":"2019","journal-title":"Oral Oncol"},{"issue":"10","key":"orv260002r14","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer.","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"orv260002r15","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1001\/jamaoto.2023.1937","article-title":"Performance of liquid biopsy for diagnosis and surveillance of human papillomavirus-associated oropharyngeal cancer.","volume":"149","author":"Ferrandino","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"19","key":"orv260002r16","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1158\/1078-0432.CCR-22-0562","article-title":"Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma.","volume":"28","author":"Berger","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"orv260002r17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1158\/1078-0432.CCR-21-2338","article-title":"Early HPV ctDNA kinetics and imaging biomarkers predict therapeutic response in p16+ oropharyngeal squamous cell carcinoma.","volume":"28","author":"Cao","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"orv260002r18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/cncy.22497","article-title":"Liquid biopsy for the diagnosis of HPV-associated head and neck cancer.","volume":"130","author":"Faden","year":"2022","journal-title":"Cancer Cytopathol"},{"issue":"6","key":"orv260002r19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/ajcp\/aqad185","article-title":"Assessing the feasibility of a multimodal liquid biopsy for the diagnosis of HPV-associated oropharyngeal squamous cell carcinoma.","volume":"161","author":"Lewis","year":"2024","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"orv260002r20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jmoldx.2023.11.007","article-title":"Comparing the diagnostic performance of quantitative PCR, digital droplet PCR, and next-generation sequencing liquid biopsies for human papillomavirus-associated cancers.","volume":"26","author":"Naegele","year":"2024","journal-title":"J Mol Diagn"},{"issue":"16","key":"orv260002r21","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1158\/1078-0432.CCR-24-2525","article-title":"Direct comparison of alternative blood-based approaches for early detection and diagnosis of HPV-associated head and neck cancers.","volume":"31","author":"Bryan","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"21","key":"orv260002r22","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1158\/1078-0432.CCR-19-2384","article-title":"HPV sequencing facilitates ultrasensitive detection of HPV circulating tumor DNA.","volume":"27","author":"Leung","year":"2021","journal-title":"Clin Cancer Res"},{"key":"orv260002r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.106131","article-title":"Diagnostic accuracy of FNA to determine HPV status in HPV-associated oropharyngeal squamous cell carcinoma.","volume":"134","author":"Morse","year":"2022","journal-title":"Oral Oncol"},{"issue":"3","key":"orv260002r24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(23)00013-X","article-title":"Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis.","volume":"24","author":"Mehanna","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"orv260002r25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/PAS.0000000000002134","article-title":"Circulating tumor HPV DNA in patients with head and neck carcinoma: correlation with HPV genotyping.","volume":"48","author":"Mijares","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"orv260002r26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1158\/1078-0432.CCR-21-3151","article-title":"Cell-free HPV DNA provides an accurate and rapid diagnosis of HPV-associated head and neck cancer.","volume":"28","author":"Siravegna","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"orv260002r27","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jamaoto.2024.2702","article-title":"Diagnostic accuracy of circulating tumor HPV DNA testing in patients with a lateral neck mass.","volume":"150","author":"Ferrandino","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"5","key":"orv260002r28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.5858\/arpa.2017-0286-CP","article-title":"Human papillomavirus testing in head and neck carcinomas: guideline from the College of American Pathologists.","volume":"142","author":"Lewis","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"orv260002r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106357","article-title":"The use of plasma circulating tumor DNA for early detection of oligometastatic disease in HPV positive oropharyngeal squamous cell carcinoma.","volume":"139","author":"Zhang","year":"2023","journal-title":"Oral Oncol"},{"key":"orv260002r30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.966899","article-title":"Current perspectives on recurrent HPV-mediated oropharyngeal cancer.","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"orv260002r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106464","article-title":"Atypical metastases highlight the true potential of ctDNA liquid biopsies for cancer monitoring.","volume":"144","author":"Zhao","year":"2023","journal-title":"Oral Oncol"},{"key":"orv260002r32","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389718","article-title":"Personalizing surveillance in head and neck cancer.","volume":"43","author":"Hanna","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"17","key":"orv260002r33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21170","article-title":"PET-NECK: a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2\/N3) nodal metastases in patients with squamous cell head and neck cancer.","volume":"21","author":"Mehanna","year":"2017","journal-title":"Health Technol Assess"},{"key":"orv260002r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106874","article-title":"Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.","volume":"155","author":"Roof","year":"2024","journal-title":"Oral Oncol"},{"key":"orv260002r35","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00450","article-title":"Evolving use of circulating tumor DNA for HPV+ oropharyngeal carcinoma: consensus recommendations from the California Head and Neck Consortium.","author":"Ho","journal-title":"JCO Oncol Pract"},{"key":"orv260002r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105721","article-title":"The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: a simulation.","volume":"126","author":"Ward","year":"2022","journal-title":"Oral Oncol"},{"issue":"12","key":"orv260002r37","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1001\/jamaoncol.2023.4042","article-title":"Circulating tumor HPV DNA for surveillance of HPV-positive oropharyngeal squamous cell carcinoma: a narrative review.","volume":"9","author":"Lang Kuhs","year":"2023","journal-title":"JAMA Oncol"},{"issue":"9","key":"orv260002r38","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1078-0432.CCR-24-3053","article-title":"A prospective trial of biomarker-guided surveillance for HPV-positive oropharynx cancer using plasma tumor tissue-modified viral HPV DNA.","volume":"31","author":"Rettig","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"853","key":"orv260002r39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aec1724","article-title":"Clinical validation of an HPV whole-genome sequencing assay for MRD detection in patients with HPV+ head and neck cancer treated with surgery.","volume":"18","author":"Hirayama","year":"2026","journal-title":"Sci Transl Med"},{"key":"orv260002r40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1373905","article-title":"Human papillomavirus circulating tumor DNA assays as a mechanism for head and neck cancer equity in rural regions of the United States.","volume":"14","author":"Windon","year":"2024","journal-title":"Front Oncol"},{"issue":"10","key":"orv260002r41","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/jamaoto.2019.1934","article-title":"Association of NCCN-recommended posttreatment surveillance with outcomes in patients with HPV-associated oropharyngeal squamous cell carcinoma.","volume":"145","author":"Masroor","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"orv260002r42","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ijrobp.2022.02.012","article-title":"Detectable postoperative circulating tumor human papillomavirus DNA and association with recurrence in patients with HPV-associated oropharyngeal squamous cell carcinoma.","volume":"113","author":"Routman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"orv260002r43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jamaoto.2024.0740","article-title":"Circulating tumor HPV DNA in patients with stage I and II HPV-associated head and neck cancer after surgery.","volume":"150","author":"Naegele","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"7","key":"orv260002r44","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamaoto.2025.0903","article-title":"ctDNA and recurrence risk for adjuvant de-escalation in HPV-positive oropharyngeal carcinoma: a secondary analysis of the DART phase 3 randomized clinical trial.","volume":"151","author":"Routman","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"11","key":"orv260002r45","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/cncr.34109","article-title":"Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer.","volume":"128","author":"O\u2019Boyle","year":"2022","journal-title":"Cancer"},{"key":"orv260002r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2026.107984","article-title":"Clearance of circulating HPV DNA during chemoradiation using a next-generation sequencing liquid biopsy.","volume":"178","author":"Bakhtiar","year":"2026","journal-title":"Oral Oncol"},{"issue":"4","key":"orv260002r47","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1245\/s10434-023-14860-y","article-title":"Circulating tumor DNA in the immediate postoperative setting.","volume":"31","author":"Efthymiou","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"orv260002r48","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ijrobp.2025.09.044","article-title":"Postoperative human papilloma virus circulating tumor DNA guided adjuvant therapy for human papilloma virus-related oropharyngeal carcinoma (PATH study).","volume":"124","author":"Chen","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"orv260002r49","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamaoto.2025.0923","article-title":"The challenge and promise of circulating tumor HPV DNA for minimal residual disease detection-catching the unseen.","volume":"151","author":"Lee","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"1","key":"orv260002r50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/jnci\/djaf249","article-title":"Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus-associated oropharynx cancer early detection.","volume":"118","author":"Das","year":"2026","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"orv260002r51","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.3390\/cancers15072051","article-title":"Circulating tumor DNA in head and neck squamous cell carcinoma.","volume":"15","author":"Brandt","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"20","key":"orv260002r52","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1158\/1078-0432.CCR-23-1478","article-title":"Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance.","volume":"29","author":"Hanna","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"orv260002r53","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamaoto.2022.3282","article-title":"Association of pretreatment circulating tumor tissue-modified viral HPV DNA with clinicopathologic factors in HPV-positive oropharyngeal cancer.","volume":"148","author":"Rettig","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"orv260002r54","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106417","article-title":"Relationship of HPV16 E6 seropositivity with circulating tumor tissue modified HPV16 DNA before head and neck cancer diagnosis.","volume":"141","author":"Rettig","year":"2023","journal-title":"Oral Oncol"},{"issue":"7","key":"orv260002r55","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/ijc.33996","article-title":"Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer.","volume":"151","author":"Rettig","year":"2022","journal-title":"Int J Cancer"},{"issue":"1","key":"orv260002r56","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/jnci\/djaf302","article-title":"Liquid biopsy for very early detection of HPV-associated oropharyngeal cancer.","volume":"118","author":"Routman","year":"2026","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"orv260002r57","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/path.5249","article-title":"Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker.","volume":"247","author":"Lam","year":"2019","journal-title":"J Pathol"},{"issue":"2","key":"orv260002r58","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ijrobp.2019.02.043","article-title":"Circulating tumor DNA to personalize treatment in nasopharynx cancer - time to look \u201cahead\u201d?","volume":"104","author":"Chua","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"orv260002r59","first-page":"3254","article-title":"Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma.","volume":"9","author":"To","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"24","key":"orv260002r60","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.","volume":"350","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"orv260002r61","doi-asserted-by":"publisher","first-page":"21976","DOI":"10.1038\/s41598-020-78892-0","article-title":"Association of Epstein-Barr virus infection with peripheral immune parameters and clinical outcome in advanced nasopharyngeal carcinoma.","volume":"10","author":"Tao","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"orv260002r62","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer.","volume":"377","author":"Chan","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"orv260002r63","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDe2300077","article-title":"Epstein-Barr virus DNA screening in asymptomatic people without known nasopharyngeal cancer.","volume":"2","author":"Izumchenko","year":"2023","journal-title":"NEJM Evid"},{"issue":"12","key":"orv260002r64","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.3390\/cancers14122968","article-title":"The promise of circulating tumor DNA in head and neck cancer.","volume":"14","author":"Aulakh","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"orv260002r65","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/jnci\/djaa198","article-title":"Cost-effectiveness of nasopharyngeal carcinoma screening with Epstein-Barr virus polymerase chain reaction or serology in high-incidence populations worldwide.","volume":"113","author":"Miller","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"orv260002r66","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1116143","article-title":"The role of Epstein-Barr virus in nasopharyngeal carcinoma.","volume":"14","author":"Su","year":"2023","journal-title":"Front Microbiol"},{"key":"orv260002r67","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.107057","article-title":"Human papillomavirus-associated nasopharyngeal carcinoma: a systematic review and meta-analysis.","volume":"159","author":"Zhao","year":"2024","journal-title":"Oral Oncol"},{"key":"orv260002r68","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3332\/ecancer.2022.1479","article-title":"Epstein-Barr virus dynamics and its prognostic impact on nasopharyngeal cancers in a non-endemic region.","volume":"16","author":"Ganapathi","year":"2022","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"orv260002r69","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/jnci\/djad012","article-title":"Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions.","volume":"115","author":"Lam","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"orv260002r70","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70641","article-title":"Health economic evaluations of circulating tumor DNA testing for cancer screening: systematic review.","volume":"14","author":"Rui","year":"2025","journal-title":"Cancer Med"},{"issue":"1","key":"orv260002r71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cncr.31741","article-title":"Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.","volume":"125","author":"Guo","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"orv260002r72","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ijrobp.2019.01.007","article-title":"Plasma Epstein-Barr virus DNA load after induction chemotherapy predicts outcome in locoregionally advanced nasopharyngeal carcinoma.","volume":"104","author":"Huang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"orv260002r73","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/annonc\/mdu117","article-title":"Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.","volume":"25","author":"Leung","year":"2014","journal-title":"Ann Oncol"},{"key":"orv260002r74","doi-asserted-by":"publisher","first-page":"22000","DOI":"10.1038\/srep22000","article-title":"Prognostic impact of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy.","volume":"6","author":"Peng","year":"2016","journal-title":"Sci Rep"},{"issue":"11","key":"orv260002r75","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1200\/JCO.21.01467","article-title":"Deintensified chemoradiotherapy for pretreatment Epstein-Barr virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase II randomized noninferiority trial.","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"orv260002r76","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1038\/s41467-019-11853-y","article-title":"Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma.","volume":"10","author":"Lv","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"orv260002r77","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2015.08.003","article-title":"The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma.","volume":"93","author":"Liu","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"27","key":"orv260002r78","doi-asserted-by":"publisher","first-page":"42608","DOI":"10.18632\/oncotarget.9323","article-title":"Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA.","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"orv260002r79","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/cncr.32770","article-title":"Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma.","volume":"126","author":"Chen","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"orv260002r80","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12916-021-02076-4","article-title":"Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA.","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med"},{"key":"orv260002r81","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.105177","article-title":"Global incidence trends in head and neck cancer for HPV-related and -unrelated subsites: a systematic review of population-based studies.","volume":"115","author":"Menezes","year":"2021","journal-title":"Oral Oncol"},{"issue":"13","key":"orv260002r82","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.3390\/cancers13133118","article-title":"Prevalence of DNA repair gene mutations in blood and tumor tissue and impact on prognosis and treatment in HNSCC.","volume":"13","author":"Burcher","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15","key":"orv260002r83","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1158\/1078-0432.CCR-21-0110","article-title":"Tumor-na\u00efve multimodal profiling of circulating tumor DNA in head and neck squamous cell carcinoma.","volume":"27","author":"Burgener","year":"2021","journal-title":"Clin Cancer Res"},{"key":"orv260002r84","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2023.101895","article-title":"Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in laryngeal squamous cell carcinoma.","volume":"67","author":"Huang","year":"2023","journal-title":"Mol Cell Probes"},{"issue":"188","key":"orv260002r85","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejca.2023.04.014","article-title":"Circulating tumour DNA kinetics in recurrent\/metastatic head and neck squamous cell cancer patients.","volume":"188","author":"Taylor","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"orv260002r86","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41551-022-00855-9","article-title":"Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth.","volume":"6","author":"Gydush","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"16","key":"orv260002r87","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1158\/1078-0432.CCR-25-0307","article-title":"Early postoperative minimal residual disease detection with MAESTRO is associated with recurrence and worse survival in patients with head and neck cancer.","volume":"31","author":"Sim","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"orv260002r88","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.annonc.2024.08.2348","article-title":"Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies.","volume":"36","author":"Liu","year":"2025","journal-title":"Ann Oncol"},{"issue":"15","key":"orv260002r89","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-24-0590","article-title":"Personalized ctDNA for monitoring disease status in head and neck squamous cell carcinoma.","volume":"30","author":"Hanna","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"8","key":"orv260002r90","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41416-022-01716-7","article-title":"Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.","volume":"126","author":"Flach","year":"2022","journal-title":"Br J Cancer"},{"issue":"3","key":"orv260002r91","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jamaoto.2025.4837","article-title":"Prognostic value of tumor-informed circulating tumor DNA in HPV-independent head and neck squamous cell carcinoma.","volume":"152","author":"Ruiz-Torres","year":"2026","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"2","key":"orv260002r92","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ohn.760","article-title":"ctDNA as an adjunct to posttreatment PET for head and neck cancer recurrence risk assessment.","volume":"171","author":"Lele","year":"2024","journal-title":"Otolaryngol Head Neck Surg"},{"key":"orv260002r93","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2025.107760","article-title":"Circulating tumor DNA in non-viral head and neck squamous cell carcinoma: a systematic review and meta-analysis.","volume":"170","author":"Helou","year":"2025","journal-title":"Oral Oncol"},{"issue":"21","key":"orv260002r94","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1002\/cam4.4726","article-title":"Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma.","volume":"11","author":"Kogo","year":"2022","journal-title":"Cancer Med"},{"key":"orv260002r95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113372","article-title":"Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and\/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor.","volume":"195","author":"Honor\u00e9","year":"2023","journal-title":"Eur J Cancer"},{"issue":"9","key":"orv260002r96","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3390\/biom13091418","article-title":"Mutated TP53 in circulating tumor DNA as a risk level biomarker in head and neck squamous cell carcinoma patients.","volume":"13","author":"Kampel","year":"2023","journal-title":"Biomolecules"},{"issue":"4","key":"orv260002r97","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ijc.35152","article-title":"Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re-radiotherapy.","volume":"156","author":"Janke","year":"2025","journal-title":"Int J Cancer"},{"issue":"16","key":"orv260002r98","doi-asserted-by":"publisher","first-page":"6056","DOI":"10.1200\/JCO.2024.42.16_suppl.6056","article-title":"Personalized circulating tumor (ct)DNA for monitoring disease status in HPV-negative head and neck squamous cell carcinoma.","volume":"42","author":"Hanna","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"orv260002r99","doi-asserted-by":"publisher","first-page":"551","DOI":"10.21873\/cdp.10254","article-title":"Circulating plasma cell-free DNA (cfDNA) as a predictive biomarker for radiotherapy: results from a prospective trial in head and neck cancer.","volume":"3","author":"Koukourakis","year":"2023","journal-title":"Cancer Diagn Progn"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2851926\/jamaotolaryngology_kansara_2026_rv_260002_1792598885.55001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:00:22Z","timestamp":1792681222000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2851926"}},"subtitle":["A Review From the American Head and Neck Society"],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":99,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2026.2045","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}